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patients receiving 45 mg and 76.9% of those receiving 90 mg
experienced a reduction of 5 points in DLQI score, signifying an
important difference, compared with 21.4% for placebo (each
p < 0.001 versus placebo). All DLQI scores improved from
baseline to Week 12 in each active treatment group compared
with placebo (each p < 0.001 versus placebo). Improvements
were observed in clinical parameters, HADS, and WLQ.
CONCLUSION: Ustekinumab resulted in signiﬁcant and clini-
cally meaningful improvements in QOL within 1 month after
starting treatment; improvements at Week 12 were maintained
through Week 24. Improvements were also observed in anxiety,
depression, and work limitations.
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OBJECTIVE: Patient–reported outcome measures, in particular
those evaluating health-related quality of life (HrQoL) , have
been proposed as a mean of facilitating doctor-patient commu-
nication. While these measures are commonly included in clinical
research studies, their use in clinical practice is still quite limited.
Our objective is to assess HrQoL in a dermatological clinic daily
routine and to develop an appropriate and effective reporting
tool for health personnel. METHODS: First phase: patients
were invited to complete the Skindex-29, GHQ-12, and SF-36
questionnaires. Scores were returned to the clinical staff. Second
phase: the patients’ medical records were reviewed to verify
which issues (e.g., pain, itch, bleeding, sleep loss, functional
limitations, fatigue) highlighted by the questionnaires were
recorded/neglected by physicians. Third phase: we developed a
check list (presence/absence) of symptoms, emotions or func-
tional problems to be ﬁlled by health personnel to complete the
routine clinical records. RESULTS: For 170 participants (63%
males, 35% age > 64 years), feedback forms were provided
within three hours from data collection. We analyzed data for
126 patients with the most common conditions: psoriasis
(n = 40), dermatitis (n = 30), leg ulcers (n = 13), pemphigus
(n = 22), cutaneous lymphoma (n = 21). Overall, sensitivity of
medical records in identifying patients’ problems ranged from
zero for most issues (including sleep loss, sex life, bleeding), to
3% for burning, 10% for depression, 15% for pain, and 35% for
itching. A 30-item checklist (a synthesis of the three question-
naires) was developed and tested in 100 patients who completed
their Skindex-29 questionnaire. The sensitivity and speciﬁcity of
physicians’ records increased for each issue, ranging from 7%
(humiliation) to 81% (itching). CONCLUSION: The routine
assessment of HrQoL in dermatology is feasible. The checklist
induced the staff to report on medical records often-neglected
patients’ problems. The checklist increased substantially the sen-
sitivity of physicians in identifying patients’ problems.
PSS32
QUALITY OF LIFE AND PSYCOLOGICAL DISTRESS IN
PATIENTWITH CUTANEUOS LYMPHOMA
Sampogna F1, Frontani M1, Baliva G1, Russo G1, Di Pietro C1,
Abeni D1,Tabolli S2
1IDI IRCCS, Rome, Italy, 2IDI IRCCS, ROME, Italy
OBJECTIVE: Cutaneous lymphomas may have a profound
impact on patients’ health-related quality of life (HRQoL) and
psychological well-being. A detailed investigation of HRQoL,
analyzing its correlation with clinical variables and biological
parameters, has not been done before. METHODS: The study
population consisted of patients with cutaneous T- cell (CTCL)
or B-cell lymphoma (CBCL), consecutively recruited in the
outpatient and the inpatient clinics of an Italian hospital. Data
was collected using a dermatology-speciﬁc questionnaire, the
Skindex-29 (symptoms, emotions, and functioning scales), and
an oncology-speciﬁc questionnaire, the EORTC QLQ-C30 (15
scales, concerning physical and emotional aspects). RESULTS:
Of 95 patients, there were 24 patients with CBCL, 59 with
mycosis fungoides (MF), and 12 with Sézary syndrome (SS). The
most frequent problems appearing from the EORTC QLQ-C30
analysis were fatigue, pain, and insomnia. The differences among
hystotypes were particularly high in the global health status and
emotional functioning scales, with a worse HRQoL in patients
with SS, followed by MF, and CBCL. HRQoL impairment in all
hystotypes was higher in women than in men, in patients with
probable anxiety or depression, and when the disease worsened.
The multivariate analysis of the independent role of each variable
conﬁrmed these results. The highest prevalence of probable
anxiety or depression was observed in patients treated with sys-
temic steroids (60%) and interferon (50%). CONCLUSION:
The detailed evaluation of HRQoL and psychological problems
in patients with cutaneous lymphomas, and their relationship
with clinical variables, may give important information on the
course of the disease as well as the possible effect of treatment.
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OBJECTIVE: To develop an internationally validated Quality of
Life (QoL) instrument speciﬁc to cosmetology and personal
appearance. This instrument will allow to measure the impact
of the use of cosmetic products in various QoL dimensions.
METHODS: Several studies have demonstrated the positive
impact of cosmetic products in dimensions. However, no speciﬁc
instrument exists to assess the main QoL dimensions in the
general population of cosmetic users. The BeautQol question-
naire is designed to be a multi-dimensional, self-administered
QoL questionnaire developed simultaneously in 13 countries.
The questionnaire focuses on concerns identiﬁed by users using
cosmetic products or cosmetic techniques. Semi directive inter-
views were carried out simultaneously in 10 countries with a
total of 309 users by clinical psychologists in France (32), UK
(18), Germany (46), Spain (27), Sweden (19), Russia (16), USA
(53), Brazil (32), Japan (48), and China (18). Interviews have
been audio or video recorded and reported in a standard format
report. Interviews were analyzed both semantically and using
text-mining techniques (Alceste software). RESULTS: From the
analysis of the 10 interview country reports, 61 items were
selected leading to 61 questions in the prototype questionnaire
describing major domains such as well being, self esteem, social
life, love life, sexual life, conﬁdence, happiness, image, status,
emotion, seduction, success, vitality, charisma, motivation, joy,
fun, dignity, etc. Three additional countries joined the project
(India, South Africa and Italy). The acceptability study is cur-
rently in progress with 650 users. The planned validation study
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will include a minimum of 2600 users worldwide. CONCLU-
SION: BeautyQol is the ﬁrst and, to date, the only user centered
instrument speciﬁc in cosmetology that is being developed simul-
taneously in 13 countries. BeautyQol is going to be a very valu-
able tool for national and international assessment of various
cosmetic strategies.
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Quality of life (QoL) in patients with dermatological conditions
is evaluated using generic and speciﬁc instruments. Even though
these instruments are created to give as a result one or more
total scores, the analysis of the answers to the single items may
give important information on QoL impairment of patients.
OBJECTIVES: To investigate the QoL of patients with vitiligo,
also analyzing single questions from a QoL instrument.
METHODS: Single items from the Skindex-29 questionnaire, a
QoL dermatology-speciﬁc instrument, were analyzed in 181
patients with vitiligo. Answers to the Skindex-29 items were
given on a 5-point scale, from “never” to “all the time”.
RESULTS: The QoL problems more frequently experienced
often or all the time were: worry of the disease getting worse
(60%) or being a serious condition (40%), anger (37%), embar-
rassment (34%), depression (31%), affect on having social life
affected (28%), and shame (28%). The association of QoL
impairment with the probable presence of depression or anxiety,
evaluated using the 12-item General Health Questionnaire
(GHQ-12), was very strong for all the items, and remained
signiﬁcant also when taking into account simultaneously gender,
age, clinical severity, family history, and localization of vitiligo.
CONCLUSION: The answers to single items from a
dermatology-speciﬁc quality of life questionnaire may provide
clinicians with relevant additional information on the physical
and mental health status of patients.
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OBJECTIVE: Chronic diseases have a long-term negative impact
on quality of life (QoL). Few studies have investigated the impact
of glaucoma on patients’ QoL in comparison to other chronic
diseases observed in patients with similar demographics. We
performed a systematic literature search to assess QoL in glau-
coma, osteoporosis, type 2 diabetes mellitus, and dementia.
METHODS: We searched MEDLINE, BIOSIS, EMBASE, and
Cochrane databases. RESULTS: A total of 146 QoL publications
were identiﬁed (some reported >1 instrument): Short-Form
Health Survey [SF]-36 was used in 77 (glaucoma = 8; osteoporo-
sis = 25; diabetes = 40; dementia = 4), SF-12 in 19 (glau-
coma = 1, osteoporosis = 5, diabetes = 9, dementia = 4), SF-20
in 7 (glaucoma = 1, diabetes = 6), EuroQol EQ-5D in 29 (glau-
coma = 2; osteoporosis = 9; diabetes = 9; dementia = 9), Sickness
Impact Proﬁle (SIP) in 6 (glaucoma = 2; osteoporosis = 1; diabe-
tes = 3, dementia = 0), and Health Utilities Index-Mark III
(HUI-III) in 17 (glaucoma + diabetes = 1; diabetes only = 11;
osteoporosis = 3; dementia = 2). Similar trends were observed
across studies using SF-36, -12 or -20: social functioning
domains were affected least, and physical domains affected most
in glaucoma. In general, QoL was affected to a similar degree in
all diseases. By EQ-5D, in glaucoma, utility decreased with
increasing glaucomatous damage. The highest mean values using
EQ-5D were similar across all four diseases; mean overall utility
scores were generally slightly lower (QoL impacted more) in
osteoporosis, diabetes and dementia than glaucoma. Mean SIP
scores increased (QoL decreased) with increasing severity of
glaucoma. Total SIP scores for glaucoma were similar to those for
diabetes. By HUI-III, QoL impact also was similar in glaucoma
and diabetes. CONCLUSION: QoL in glaucoma decreases with
increasing disease severity; physical domains are affected more
than social domains. Although there are limited published QoL
studies in glaucoma, its impact on QoL appears to be broadly
consistent with other serious chronic diseases. Further efforts
towards diagnosing and treating glaucoma, to reduce ﬁnancial
burden on health care systems and society, are warranted.
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OBJECTIVE: Vision disorders have a negative impact on quality
of life (QoL). While the impairment of QoL in central-vision loss
(CVL) disorders, e.g. age-related macular degeneration (ARMD),
is widely acknowledged, the QoL impact of peripheral-vision
loss (PVL) disorders, e.g. glaucoma, is less well-known. We per-
formed a systematic literature search to assess the effect on
QoL of PVL versus CVL. METHODS: We searched MEDLINE,
BIOSIS, EMBASE, and Cochrane databases. RESULTS: A total
of 87 publications were identiﬁed (some reported >1 instrument):
Short-Form Health Survey (SF)-36 was used in 23 (PVL = 2;
CVL = 21), SF-12 in 6 (PVL = 1; CVL = 5), National Eye Insti-
tute Visual Function Questionnaire (NEI-VFQ)-51 in 11
(PVL = 4; CVL = 7), NEI-VFQ-39 in 9 (PVL = 1; CVL = 8), NEI-
VFQ-25 in 36 (PVL = 11; CVL = 25), EuroQol EQ-5D in 3
(PVL = 1; CVL = 2), Visual Function-14 (VF-14) in 20 (PVL = 1;
CVL = 19), Sickness Impact Proﬁle (SIP) in 4 (PVL = 2 [1 study];
CVL = 2), and Impact of Vision Impairment (IVI) in 1 (including
3 diseases: glaucoma, retinopathy [PVL] and ARMD [CVL]). By
SF-36, vitality was impacted most in PVL. By SF-36 and SF-12,
generally, mental health domains were affected more in PVL than
CVL; physical domains were affected most in CVL. Mental
aspects of QoL were affected more in PVL than CVL in all
NEI-VFQ studies; ARMD and glaucoma impacted different
domains. QoL was generally lower in glaucoma than ARMD,
although results varied amongst studies. By EQ-5D, QoL in
PVL and CVL were similarly affected. By VF-14 and SIP, CVL
impacted QoL slightly more than PVL. By SIP, psychosocial and
physical domains were affected equally in PVL. In the IVI study,
PVL affected QoL slightly more than CVL (except glaucoma on
the social scale). CONCLUSION: Results showed in general,
PVL and CVL disorders have a signiﬁcant impact on QoL. More
QoL research towards better understanding patients’ concerns
with their PVL and CVL disorders are warranted.
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OBJECTIVE: The purpose of this study was to conduct a statis-
tical mapping between patient reported disease-speciﬁc quality of
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